MASIMO CORPORATION (NASDAQ:MASI) Files An 8-K Results of Operations and Financial Condition
Item 2.02.
Results of Operations and Financial Conditions.
On January9, 2019, Masimo Corporation (the “Company”), issued a press release announcing certain preliminary financial results for the fourth quarter ended December 29, 2018. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The preliminary financial information presented in this press release is based on the Company’s current expectations and may be adjusted as a result of, among other things, completion of customary annual audit procedures. The Company’s management plans to discuss the Company’s complete fourth quarter 2018 financial results after the market closes on Tuesday, February 26, 2019.
In accordance with General Instructions B.2 of Form 8-K, the information in Item 2.02 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
|
Item 9.01. |
Financial Statements and Exhibits. |
MASIMO CORP Exhibit
EX-99.1 2 masi-20190109xex991.htm EXHIBIT 99.1 Exhibit Exhibit 99.1Masimo Announces Select Preliminary Full-Year 2018 Financial Results and 2019 OutlookComplete fourth quarter and full year 2018 financial results will be announced on Tuesday,…
To view the full exhibit click here
About MASIMO CORPORATION (NASDAQ:MASI)
Masimo Corporation is a medical technology company that develops, manufactures and markets non-invasive patient monitoring products. The Company’s business is measure-through-motion and low-perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry. Its product offerings include monitoring blood constituents with an optical signature, optical organ oximetry monitoring, electrical brain function monitoring, acoustic respiration monitoring and exhaled gas monitoring. The Company has developed the Root patient monitoring and connectivity platform, the Radical-7 bedside and portable patient monitor and the Radius-7 wearable wireless patient monitor. It has also developed the Patient SafetyNet remote patient surveillance monitoring system, which allows over 200 patients to be monitored simultaneously and remotely through a personal computer (PC)-based viewing station or by care providers through their voice-over-Internet Protocol (IP) phones.
